In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
13 authors.
Jay R AnandDepartment of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0003-2071-9891 Bethany Wagner BrownDepartment of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0001-7893-5381 Jitong LouDepartment of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-1049-0416 Qisheng GuDivision of Oral and Craniofacial Health Sciences, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0001-7294-042X Yang YangDepartment of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-5936-4090 Gaith DrobyCurriculum in Genetics and Molecular Biology, University of North Carolina, Chapel Hill, NC 27599, USA.ORCID 0000-0003-0116-0340 Di WuDivision of Oral and Craniofacial Health Sciences, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0001-8331-2357 Akankshya JenaDepartment of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-5521-2655 Jialiu XieDepartment of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-0560-7982 Yuri FedoriwDepartment of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-2135-2908 Bernard WeissmanDepartment of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-1827-2309 Scott WilliamsDepartment of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0001-9975-7334 Cyrus VaziriDepartment of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-3081-8685 Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5MUNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Hazel B Nichols · 2001 to 2026
$36.3MA Novel Carcinogen-Induced Cell Cycle CheckpointR01ES009558 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI VAZIRI, CYRUS · 2002 to 2016
$4.8MDefining Mechanisms of Pathological Trans-Lesion Synthesis During CarcinogenesisR01CA215347 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI VAZIRI, CYRUS, WILLIAMS, SCOTT E · 2018 to 2022
$2.6MEstablishing MAGE-A4/RAD18 as a novel cancer-specific chemotherapeutic targetR01CA229530 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PEARCE, KENNETH HUGH, VAZIRI, CYRUS · 2019 to 2023
$2.0MNCI NIH HHS P30 CA016086NCI NIH HHS R01 CA215347NCI NIH HHS R01 CA229530NIEHS NIH HHS P30 ES010126NIEHS NIH HHS R01 ES009558
6 · The paper itselfAbstract
The DNA repair protein RAD18 activates 'Y-family' Trans-Lesion Synthesis (TLS) DNA polymerases that are DNA damage-tolerant and potentially error-prone. RAD18 is also frequently overexpressed and pathologically activated in cancer cells. However, the extent to which RAD18 shapes cancer genomes and impacts tumorigenesis is unclear. Therefore, we tested the effect of
Identifiers
PMID40631250
PMCPMC12236731
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390